The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Can Oncotype DX recurrence score (RS) be used in luminal A and luminal B breast cancer patients (pts) to predict the likely benefit of chemotherapy? A retrospective study in the Spanish population.
Laura García-Estevez
No relevant relationships to disclose
Ana C Contreras
No relevant relationships to disclose
Isabel Calvo
No relevant relationships to disclose
Maria Fernandez Abad
No relevant relationships to disclose
Juan J de la Cruz
No relevant relationships to disclose
Sofia Perea
No relevant relationships to disclose
Ana Suárez
No relevant relationships to disclose
Fernando López-Ríos
No relevant relationships to disclose
Manuel Hidalgo
No relevant relationships to disclose